Good
Mostly Aligned
Patient Risk:
Moderate
Summary
Most statements about Otrexup being methotrexate, its injection/autoinjector administration, pregnancy contraindication, toxicity/warnings themes, and laboratory monitoring are supported by the provided label text. Several claims are not supported because the provided label excerpts omit the Indications section and some wording is not explicit (e.g., 'prefilled', 'prescriber determines exact dose schedule', medication review, and exclusivity/pricing).
Category Scores
Accurate Statements
Otrexup is a brand of methotrexate.
11 DESCRIPTION; 2.1 Important Dosing Information
Otrexup is administered by injection using the autoinjector.
2.1 Important Dosing Information; 2.4 Administration and Handling; 3 DOSAGE FORMS AND STRENGTHS
Otrexup contains methotrexate.
11 DESCRIPTION; 3 DOSAGE FORMS AND STRENGTHS
Common methotrexate safety concerns include liver and blood cell effects.
5.1 Organ System Toxicity; 17 PATIENT COUNSELING INFORMATION (risk of organ toxicity including hepatic and hematologic)
Common methotrexate safety concerns include stomach side effects.
5.1 Organ System Toxicity (Gastrointestinal section); 6 ADVERSE REACTIONS (ulcerative stomatitis, abdominal distress)
Methotrexate is generally contraindicated in pregnancy.
4 CONTRAINDICATIONS (Pregnancy); boxed warning text (Use is contraindicated during pregnancy)
Drug interactions can increase methotrexate toxicity.
Boxed warning (unexpectedly severe... with concomitant administration... and some NSAIDs); 5.1 Organ System Toxicity (same concept)
Monitoring for Otrexup treatment can include blood counts and liver-related labs.
5.4 Laboratory Tests (complete blood count; hepatic enzymes; liver function tests)
Unsupported Statements
Otrexup is used for conditions that respond to methotrexate therapy.
No provided label excerpt states this general criterion; Indications section content is not included.
Otrexup is used for other inflammatory diseases treated with methotrexate.
No provided label excerpt supports indications beyond rheumatoid arthritis; Indications section content is not included.
Otrexup is used for other immune-mediated diseases where methotrexate helps control symptoms and disease activity.
No provided label excerpt supports additional immune-mediated indications; Indications section content is not included.
Clinicians review other medications before and during treatment with Otrexup.
No provided label excerpt explicitly states medication review before and during treatment (as opposed to drug interaction warnings).
The availability of cheaper alternatives to Otrexup depends on the product's patent and exclusivity status.
No provided label excerpt discusses pricing, patents, or exclusivity.
Contradictions
Important Omissions
Indication details beyond rheumatoid arthritis (e.g., label-supported diseases/criteria) are not evaluated because the provided label excerpts do not include the Indications section.
Importance:
High
Explicit boxed warning content and instruction-level device/warning phrasing beyond what is contained in the provided excerpts cannot be fully assessed; one claim about 'boxed warnings' being explicitly supported by device-specific instructions is only partially supported due to limited excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several claims are unsupported or only partially supported, mainly concerning indications beyond rheumatoid arthritis and specific labeling language (e.g., 'prefilled', prescriber-determined dosing schedule, medication review). While these do not directly contradict contraindications/warnings supported in the excerpts, they could lead to inaccurate labeling interpretation.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Unsupported/additional indication claims and several labeling-language claims not explicitly supported by the provided excerpts (e.g., prefilled wording, prescriber-determined schedule wording, medication review, and patent/exclusivity/pricing).
Suggested Improvement
Limit claims to the diseases/indications explicitly stated in the provided Indications section (not supplied here), avoid implying 'prefilled' unless explicitly stated, avoid prescriber-determined dose-schedule phrasing unless present verbatim, omit any statement about medication review unless explicitly described, and remove any discussion of patents/exclusivity/pricing not found in the label.